MDRI gene expression as pharmacogenetic marker to predict response and progression-free survival on 2nd line nilotinib therapy in imatinib-resistant CML-4-year follow-up.

被引：0

|

作者：

Agrawal, M. ^{[1
]}

Hanfstein, B. ^{[1
]}

Erben, P. ^{[1
]}

Saussele, S. ^{[1
]}

Hehlmann, R. ^{[1
]}

Fabarius, A. ^{[1
]}

Hofmann, W-K ^{[1
]}

Hochhaus, A. ^{[2
]}

Mueller, M. C. ^{[1
]}

机构：

[1] Heidelberg Univ, Univ Med Mannheim, Med Fak Mannheim, Med Klin 3, Mannheim, Germany

[2] Univ Klinikum, Klin Innere Med 2, Jena, Germany

来源：

ONKOLOGIE | 2013年 / 36卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：99 / 99

页数：1

相关论文

共 3 条

[1] MDR1 expression serves as a pharmacogenetic marker for the prediction of molecular, cytogenetic and clinical outcome on 2nd line nilotinib therapy in imatinib-resistant CML patients
Agrawal, M.
Erben, P.
Hanfstein, B.
Popa, J.
Hofmann, W-K
Leitner, A.
Hochhaus, A.
Mueller, M. C.
ONKOLOGIE, 2010, 33 : 144 - 144
[2] MDR1 expression serves as a pharmacogenetic marker for the prediction of molecular, cytogenetic and clinical outcome on 2nd line nilotinib therapy in imatinib-resistant CML patients
Agrawal, M.
Erben, P.
Hanfstein, B.
Popa, J.
Hofmann, W. K.
Leitner, A.
Hochhaus, A.
Mueller, M. C.
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 : 86 - 86
[3] MDR1 Gene Expression Predicts Response and Progression-Free Survival Of Ph plus CML Patients On Second-Line Nilotinib Therapy After Imatinib Failure-4-Year Follow-Up
Agrawal, Mridul
Hanfstein, Benjamin
Erben, Philipp
Wolf, Dominik
Ernst, Thomas
Saussele, Susanne
Fabarius, Alice
Purkayasatha, Das
Woodman, Richard C.
Hehlmann, Ruediger
Hofmann, Wolf-Karsten
Hochhaus, Andreas
Mueller, Martin C.
BLOOD, 2013, 122 (21)